Article Contents ::
Details About Generic Salt :: Azacitidine
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
| 18A. ANTI-NEOPLASTIC AGENTS in 18. ANTI-NEOPLASTIC AGENTS |
| AZACITIDINE |
| DNA METHYLATION INHIBITOR | ANTI-NEOPLASTIC |
| PK: A: SC: Rapid & complete D: Vd: 76±26 L(IV) M: Hepatic E: Urine (50-85%), feces (minor) |
|
Indications & Dose: MYELODYSPLASTIC SYNDROME IV/SC Adult 75mg/m2/day for 1 wk repeated q 4wks, dose may increase to 100mg/m2/day (if no benefits is observed after 2cycles/no toxicity other than nausea/vomiting) |
| Contra: Hypersensitivity, Advanced malignant hepatic tumors
Precautions: Renal impairment ADR: Serious: Peripheral edema, chest pain, pallor, pitting edema, hypokalemia, thrombocytopenia, leukopenia, febrile neutropenia, myelosuppression, arthralgia, myalgia, URTI, pneumonia, hypertension, hypotension, tachycardia, cellulitis, hemorrhoids, hematoma, herpes simplex, lymphadenopathy, post procedural hemorrhage, Others: fever, fatigue, dizziness, depression, insomnia, pain, bruising, erythema, skin lesion, nausea, vomiting, constipation, weight loss, abdominal pain, injection site reaction, weakness, back pain, dyspnea, nasopharyngitis, epistaxis, crackles, gingival bleeding, stomatitis, weight loss, dysphagia, abdominal distension, rhinorrhea, wheezing, nasal congestion, sinusitis, night sweats, tongue ulceration, mouth hemorrhage DDI: Others Pimecrolimus/Denosumab/Tacrolimus increases azacitidne levels, Vaccines (Live & inactivated)/BCG levels decreases, Vaccines (Live)/Leflunomide levels increases Monitor: LFTs, electrolytes, CBC with differential & platelets, renal function test |